Reply

Mathieu Sertorio, Rodrigo F. Carmo, Sandrine Cabantous, Luydson Vasconcelos, Leila Beltrao Pereira, Patricia Moura, Alain Dessein – 23 April 2015

The impact of pretransplant hepatic encephalopathy on survival following liver transplantation

Robert J. Wong, Maria Aguilar, Robert G. Gish, Ramsey Cheung, Aijaz Ahmed – 22 April 2015 – Hepatic encephalopathy (HE) is a surrogate marker of liver disease severity, and more severe HE is associated with higher mortality among patients with chronic liver disease. However, whether severity of HE at the time of liver transplantation (LT) directly impacts post‐LT survival or whether this suspected mortality linkage is due to more severe liver disease and subsequently higher rates of post‐LT infection is not well defined.

Nuclear factor kappa B–mediated CD47 up‐regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice

Jessica Lo, Eunice Yuen Ting Lau, Rachel Hiu Ha Ching, Bowie Yik Ling Cheng, Mark Kin Fai Ma, Irene Oi Lin Ng, Terence Kin Wah Lee – 21 April 2015 – Sorafenib is a new standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the survival benefit of this treatment is modest, partly owing to drug resistance. Recent evidence has demonstrated the existence of tumor‐initiating cells (T‐ICs) as the culprit for treatment resistance.

Subscribe to